Thomson Reuters on BillMyParents’ Investor Isaac Blech ($BMPI)
.png)
Thomson Reuters’ Accelus website recently published a piece about BillMyParents, Inc. (OTCQB: BMPI, OTCBB: BMPI, Twitter: $BMPI), acknowledging that while the brand may have an unconventional name, its executive team and board members are “well-seasoned,” and listing major points of interest from leading shareholder Isaac Blech’s impressive track record as a founding shareholder:
Mr. Blech’s achievements include:
- Celgene Corporation (NASDAQ: CELG) – Blech was a founding shareholder of Celgene, which has introduced two major cancer drugs and has a stock market valuation of approximately $27+ billion.
- ICOS Corporation – ICOS discovered the drug Cialis and was later acquired by Eli Lilly for over $2 billion. Blech was a founding shareholder.
- Nova Pharmaceutical Corporation - Nova developed a treatment for brain cancer and subsequently merged with Scios Corporation which was later purchased for $2 billion by Johnson and Johnson. Blech was a founding shareholder and a member of the Board of Directors.
- Pathogeneses Corporation – Pathogeneses created TOBI for the treatment of cystic fibrosis and was later acquired by Chiron Corp for $660 million. Blech was a founding shareholder.
- Genetic Systems Corporation – GSC developed the first inexpensive and accurate test to diagnose chlamydia and was later acquired by Bristol Myers for approximately $300 million.
Mr. Blech is BillMyParents’ leading shareholder with beneficial ownership of more than 38 million shares, and he has invested millions into the company in the form of equity injections and/or convertible notes.
BillMyParents, founded in April 2007, develops and markets innovative online and traditional retail youth payment solutions. Click here to read the full article.
For more information on BillMyParents, see their investor relations page.
ProActive Capital Indexes
See ProActive's Disclaimer